MBCC

Articles

The clinical nurse specialist was also diagnosed with stage III invasive lobular breast cancer and was treated with CDK 4/6 inhibitors, giving her the unique opportunity to speak to both the patient and clinical perspective.

Patricia Jakel, RN, MN, AOCN, On Treating Patients with CDK 4/6 Inhibitors

The geriatric oncologist spoke about the differences in treating older women and younger women with triple-negative breast cancer.

Enrique Soto Perez de Celis, MD, MSc, On Treatment for Older Women with TNBC

The breast medical oncologist discussed new treatment options for triple negative breast cancer as new targets become readily available for this aggressive cancer type.

Debu Tripathy, MD, On the Future of Triple Negative Breast Cancer Treatment

The breast oncologist from the University of California, San Francisco, discussed new agents being developed in the breast cancer space.

Hope Rugo, MD, On the Future of Breast Cancer Treatment

The breast cancer expert spoke about decreasing the amount of treatment to receive the same impact for patients with breast cancer.

Kevin Hughes, MD, on Breast Cancer Treatment Moving Forward

After a serious adverse reaction to a clinical trial put her in critical condition, Barbara Bigelow now shows no signs of breast cancer and is no longer on any cancer medications.

Barbara Bigelow Discusses her Journey with Triple Negative Breast Cancer

At the 37th Annual Miami Breast Cancer Conference, Valerie Lemaine, MD, MPH, FRCSC, told physicians what they need should know and discuss with their patients about BIA-ALCL.

What Physicians Should Know About Breast Implant-Associated Anaplastic Large Cell Lymphoma

Scott Gottlieb, MD, spoke about the spread of the novel coronavirus (COVID-19) during the keynote address at the 37th Annual Miami Breast Cancer Conference®.

Gottlieb Addresses Coronavirus at Miami Breast Cancer Conference

The goal of the study is to determine the effect of adagloxad simolenin administered with the potent adjuvant OBI-821 as a therapeutic vaccine treatment on improving invasive disease-free survival in the study population.

Study Design for the Phase III GLORIA Trial of OBI-822/OBI-821 Vaccine Combination

Aditya Bardia, MD, MPH detailed the clinical development of antibody drug conjugates in patients with metastatic triple negative breast cancer, as well as what to expect moving forward with antibody drug conjugates in the metastatic breast cancer space.

MBCC | Conference